10-Q: BWXT Reports Strong Q3 Growth Driven by Acquisitions
Quarterly Report
BWX Technologies Inc. (BWXT) announced a significant increase in third-quarter revenues and operating income, fueled by strategic acquisitions and robust performance across its Government and Commercial Operations segments.
Summary
- BWXT reported a 10.0% increase in consolidated revenues for the third quarter of 2026, reaching $953.0 million, up from $866.3 million in the same period of 2025.
- Consolidated operating income rose by $18.7 million to $132.1 million for the third quarter of 2026, compared to $113.3 million in the prior year.
- For the nine-month period ended September 30, 2026, revenues grew by 17.4% to $2,714.8 million, with operating income increasing by $40.5 million to $352.9 million.
- The Government Operations segment saw a 3.6% revenue increase in Q3 2026, driven by contributions from Aerojet Ordnance Tennessee, Inc. (A.O.T.) and enrichment operations.
- Commercial Operations segment revenues surged by 25.2% in Q3 2026, largely due to the acquisition of Precision Components Group (PCG) and increased on-site services.
- The company's backlog stood at $8,556.2 million as of September 30, 2026, with approximately 46% expected to be recognized by the end of 2027.
- BWXT completed the acquisition of Precision Components Group, LLC (PCG) on July 1, 2026, and is proceeding with the sale of its medical business, expected to close in late 2026 or early 2027.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this filing as moderately positive, reflecting solid revenue growth and improved operating income, driven by strategic acquisitions and strong performance in key segments, despite increased corporate expenses.
Positives
- Consolidated revenues increased by 10.0% to $953.0 million in Q3 2026 compared to Q3 2025.
- Consolidated operating income increased by 16.5% to $132.1 million in Q3 2026 compared to Q3 2025.
- Government Operations segment revenues grew by 3.6% to $639.1 million in Q3 2026.
- Commercial Operations segment revenues saw a substantial increase of 25.2% to $314.2 million in Q3 2026.
- The acquisition of PCG on July 1, 2026, contributed significantly to the Commercial Operations segment's revenue growth.
- The company's backlog increased to $8,556.2 million as of September 30, 2026, indicating strong future revenue potential.
- Net income attributable to BWX Technologies, Inc. increased to $101.7 million in Q3 2026 from $82.1 million in Q3 2025.
Negatives
- Unallocated corporate expenses increased by $8.8 million in Q3 2026 compared to Q3 2025, primarily due to restructuring and M&A related costs.
- The sale of the medical business, while strategic, involves a complex divestiture process.
- The company's effective tax rate for Q3 2026 was 22.7%, slightly higher than the U.S. federal statutory rate due to non-deductible executive compensation.
Risks
- As a contractor to the U.S. Government, BWXT is subject to risks related to budget uncertainty, continuing resolutions, government shutdowns, program cancellations, and changing funding priorities.
- The company's Commercial Operations segment is influenced by the demand and competitiveness of nuclear energy and the cyclical nature of capital expenditures and major refurbishment projects.
- The sale of the medical business is subject to customary regulatory approvals and may not be completed within the expected timeframe.
- The company's operations involve complex contracts with potential for changes in estimates that can impact revenues and profitability.
- The company's credit facility contains financial covenants, including a maximum consolidated total net leverage ratio and a minimum consolidated interest coverage ratio, which must be maintained.
Future Outlook
The company expects to recognize approximately 46% of its current backlog revenue by the end of 2027, with the remainder thereafter. The company believes it has sufficient cash and borrowing capacity to meet its cash requirements for the next 12 months and beyond.
Management Comments
- Consolidated revenues increased 10.0%, or $86.7 million, to $953.0 million in the three months ended September 30, 2026 compared to $866.3 million for the corresponding period of 2025, due to increases in our Government Operations and Commercial Operations segments of $22.4 million and $63.2 million, respectively.
- Consolidated operating income increased $18.7 million to $132.1 million in the three months ended September 30, 2026 compared to $113.3 million for the corresponding period of 2025, due to an increase in our Government Operations and Commercial Operations segments of $25.2 million and $2.3 million, respectively, offset partially by an increase in Unallocated Corporate expenses of $8.8 million when compared to the corresponding period in the prior year.
- Consolidated revenues increased 17.4%, or $402.2 million, to $2,714.8 million in the nine months ended September 30, 2026 compared to $2,312.6 million for the corresponding period of 2025, due to increases in our Government Operations and Commercial Operations segments of $57.3 million and $344.9 million, respectively.
- Consolidated operating income increased $40.5 million to $352.9 million in the nine months ended September 30, 2026 compared to $312.4 million for the corresponding period of 2025, due to an increase in our Government Operations and Commercial Operations segments of $22.9 million and $37.4 million, respectively, offset partially by an increase in Unallocated Corporate expenses of $19.7 million when compared to the corresponding period in the prior year.
Industry Context
StockSavvy.ai notes that BWXT's performance aligns with broader trends in the defense and nuclear energy sectors, characterized by increased government spending on national security and a growing interest in advanced nuclear technologies for both defense and commercial applications. The company's strategic acquisitions are positioning it to capitalize on these trends.
Comparison to Industry Standards
- BWXT's revenue growth of 10.0% in Q3 2026 outpaces the general manufacturing sector's typical quarterly growth rates.
- The operating margin for Government Operations (19.2% in Q3 2026) is strong and competitive within the defense contracting industry.
- The Commercial Operations segment's significant revenue growth (25.2% in Q3 2026) reflects successful integration of acquisitions and demand in the nuclear services market, which is experiencing a resurgence.
- The company's backlog of $8.56 billion is substantial and provides a strong foundation for future revenue, a key indicator of stability in the capital-intensive industries it serves.
Legal Proceedings
- No material contingencies were disclosed during the period.
Stakeholder Impact
- Shareholders are likely to view the revenue growth and improved profitability positively.
- Employees may see increased opportunities due to business expansion and integration of new entities.
- Customers, particularly U.S. Government agencies and commercial nuclear utilities, will benefit from BWXT's continued supply of critical components and services.
- Suppliers may experience increased business as BWXT expands its operations.
Next Steps
- Complete the sale of the medical business, expected in late 2026 or early 2027.
- Continue integration of acquired businesses (A.O.T., Kinectrics, PCG) to realize synergies.
- Monitor U.S. Government budget appropriations for potential impacts on the Government Operations segment.
- Focus on capitalizing on growth opportunities in advanced nuclear technologies and commercial nuclear services.
Key Dates
| Date | Description |
|---|---|
| 2025-01-03 | Acquisition of Aerojet Ordnance Tennessee, Inc. (A.O.T.) |
| 2025-05-20 | Acquisition of Kinectrics Holdings Inc. |
| 2026-07-01 | Acquisition of Precision Components Group, LLC (PCG) |
| 2026-07-31 | Definitive agreement entered into to sell the medical business |
| 2026-09-30 | Quarterly period end for the reported financial statements |
| 2026-11-02 | Filing date of the Form 10-Q |
Recommendation
holdThe company demonstrates solid execution with strong revenue growth and improved profitability, driven by strategic acquisitions and core segment performance. However, the increase in corporate expenses, the ongoing divestiture of the medical business, and the inherent risks associated with government contracting warrant a cautious approach. While the outlook is positive, the current valuation and potential integration challenges suggest a 'hold' rating pending further clarity on the long-term impact of these strategic moves.
Keywords
nuclear components, government operations, commercial operations, naval nuclear propulsion, nuclear fuel, acquisitions, revenue growth, backlog
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.